| Literature DB >> 31626632 |
F Grases1, A Costa-Bauzá1, F Berga1, R M Gomila2, G Martorell2, M R Martínez-Cignoni3.
Abstract
OBJECTIVE: To evaluate the urinary levels of inositol phosphates (InsPs) in rats that received different salts of myo-inositol hexaphosphate (InsP6) by gavage or by oral administration.Entities:
Year: 2019 PMID: 31626632 PMCID: PMC6799915 DOI: 10.1371/journal.pone.0223959
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Mass spectrum of a eluate prepared using TiO2 purification.
Rat # 6 (Group A) after 14 days of IP6Na12 administration.
Fig 2Detection of InsP6 in urine of rat by PAGE, after 14 days of InsP6Na administration (Group A, day 14).
SB (sample Buffer), S1 (Standard 1: 1.25nmols InsP6), S2 (Standard 2: 5 nmols InsP6), urine samples (rats 1A, 2A, 3A, 4A, 5A, 6A).
Concentration and excretion values of InsP6 obtained by semiquantification with polyacrylamide gel electrophoresis (PAGE).
During the collection day rats drank Tap Water with 5g/L of sucrose to increase the diuresis. Group A–administration of IP6Na12, Group B–administration of InsP6Mg2 Ca4. Values are expressed as mean ± SE. Comparison between groups were performed by independent samples t-test.
| 0.043 | 0.016 | ||
| 0.030 | 0.018 | ||
| 0.025 | 0.013 | ||
| 0.119 | 0.024 | ||
| 0.069 | 0.013 | ||
| 0.266 | 0.027 | ||
| 0.092 ± 0.038 | 0.018 ± 0.002 | 0.108 | |
| 0.492 | 0.445 | ||
| 0.435 | 0.275 | ||
| 0.331 | 0.632 | ||
| 0.831 | 0.327 | ||
| 0.963 | 0.370 | ||
| 4.929 | 0.322 | ||
| 1.330 ± 0.727 | 0.395 ± 0.053 | 0.255 | |
Excretion values obtained by non-specific spectrometric quantification of InsPs.
Group A–administration of IP6Na12 by gavage Group B–administration of InsP6Mg2 Ca4.by gavage Group C–oral administration of IP6Na12, Group D–oral administration of IP6Mg2Ca4, Group E–oral administration of IP6Na12 + Ca. Values are expressed as mean ± SE.
| [InsPs] Exc (nmol/20h) | ||||||
|---|---|---|---|---|---|---|
| Day 0 | 0.320 ± 0.131 | 0.910 ± 0.311 | 0.565 ± 0.236 | 2.553 ± 0.423 | 0.920 ± 0.379 | <0.001 |
| Day 7 | 6.925 ± 1.279 | 2.398 ± 0.537 | 0.963 ± 0.313 | 0.893 ± 0.704 | 1.611 ± 0.401 | <0.001 |
| Day 14 | 4.698 ± 1.507 | 4.840 ± 0.417 | 0.465 ± 0.329 | 0.199 ± 0.199 | 1.551 ± 0.441 | <0.001 |
| Day 21 | 4.114 ± 0.335 | 3.751 ± 0.391 | 0.447 ± 0.447 | 0.001 | ||
| Day 28 | 2.311 ± 0.365 | 1.373 ± 0.081 | 2.818 ± 0.391 | 0.125 | ||
| Day 35 | 6.369 ± 0.416 | 1.226 ± 0.213 | 4.827 ± 0.574 | <0.001 | ||
Intragroup comparisons were analyzed using one-way repeated measures ANOVA for each group. Intergroup comparisons were performed by two-way repeated measures ANOVA (at 0, 7, 14, 21, 28 and 35 days).
1: p<0.05 vs. corresponding value at day 0 (intragroup)
2: p<0.05 vs. corresponding value at day 7 (intragroup)
3: p<0.05 vs. corresponding value at day 14 (intragroup)
4: p<0.05 vs. corresponding value at day 21 (intragroup)
5: p<0.05 vs. corresponding value at day 28 (intragroup)
a: p<0.05 vs. corresponding value of group A (intergroup)
b: p<0.05 vs. corresponding value of group B (intergroup)
c: p<0.05 vs. corresponding value of group C (intergroup)
d: p<0.05 vs. corresponding value of group D (intergroup)
Fig 3Identification of InsPs by Mass Spectrometry (MS) after 7 and 14 days of administration of InsP6Na (Group A).
Mean ± SE of the values obtained by each rat.
Fig 4Identification of InsPs by Mass Spectrometry (MS) after 7 and 14 days of administration of InsP6MgCa (Group B).
Mean±SE of the values obtained by each rat.
Results of concentration obtained by non-specific spectrometric quantification of InsPs.
Group A–administration of IP6Na12 by gavage Group B–administration of InsP6Mg2 Ca4.by gavage Group C–oral administration of IP6Na12, Group D–oral administration of IP6Mg2Ca4, Group E–oral administration of IP6Na12 + Ca. Values are expressed as mean ± SE.
| [InsPs] μM | ||||||
|---|---|---|---|---|---|---|
| Day 0 | 0.047 ± 0.031 | 0.138 ± 0.100 | 0.014 ± 0.006 | 0.082 ± 0.010 | 0.039 ± 0.018 | 0.404 |
| Day 7 | 0.530 ± 0.047 | 0.162 ± 0.055 | 0.063 ± 0.043 | 0.051 ± 0.046 | 0.076 ± 0.016 | <0.001 |
| Day 14 | 0.335 ± 0.066 | 0.238 ± 0.040 | 0.216 ± 0.195 | 0.036 ± 0.036 | 0.188 ± 0.099 | 0.032 |
| Day 21 | 0.519 ± 0.134 | 0.190 ± 0.061 | 0.017 ± 0.017 | 0.012 | ||
| Day 28 | 0.173 ± 0.050 | 0.072 ± 0.031 | 0.279 ± 0.098 | 0.007 | ||
| Day 35 | 0.663 ± 0.317 | 0.167 ± 0.049 | 0.555 ± 0.175 | 0.060 | ||
Intragroup comparisons were analyzed using one-way repeated measures ANOVA for each group. Intergroup comparisons were performed by two-way repeated measures ANOVA (at 0, 7, 14, 21, 28 and 35 days).
1: p<0.05 vs. corresponding value at day 0 (intragroup)
2: p<0.05 vs. corresponding value at day 7 (intragroup)
3: p<0.05 vs. corresponding value at day 14 (intragroup)
4: p<0.05 vs. corresponding value at day 21 (intragroup)
a: p<0.05 vs. corresponding value of group A (intergroup)
b: p<0.05 vs. corresponding value of group C (intergroup)
c: p<0.05 vs. corresponding value of group D (intergroup)
Fig 5Identification of InsPs by Mass Spectrometry (MS) after 21 days of administration of InsP6Na without calcium (Group C).
InsP5 and InsP6 values obtained by each rat of the group (I) and the Mean±SE of InsP1-InsP6 (II).